Boryung Announces Winners of the 3rd Humans In Space Challenge
Boryung Announces Winners of the 3rd Humans In Space Challenge
Paving the Way as a Global Leader in Space Healthcare
作爲全球空間醫療保健領域的領導者,開闢新天地
- Introducing of a new funding model to support space experiments and strengthen research in space healthcare
- 引入新融資模式以支持空間實驗並加強空間醫療保健研究
- Hosted the final round of the Humans In Space Challenge at the 75th International Astronautical Congress
- 在第75屆國際宇航聯合會大會上舉辦了空間人類挑戰賽的決賽
SEOUL, South Korea, Dec. 18, 2024 /PRNewswire/ -- On December 18, Boryung announced the final winners of the 3rd Humans In Space (HIS) Challenge.
韓國首爾,2024年12月18日 /美通社/ -- 12月18日,博隆公司宣佈第三屆人類在空間(HIS)挑戰賽的最終獲勝者。
Now in its 3rd year, the HIS Challenge is a global space healthcare competition initiated in 2022. The program aims to gather innovative ideas to address healthcare challenges arising during space exploration and solve healthcare problems on Earth by leveraging the space environment. Outstanding teams are selected and offered investment opportunities through this initiative.
人類在空間挑戰賽已進入第三年, 是一項始於2022年的全球空間醫療保健競賽。該項目旨在收集創新理念,以應對空間探索中的醫療保健挑戰,並通過利用空間環境解決地球上的醫療保健問題。優秀團隊將通過該項倡議被選中並獲得投資機會。
This year, the HIS Challenge introduced significant changes to its prize structure compared to last year. While it provided equity investments for winning startups and research funding for research teams in 2023, it has expanded its offerings to include Orbital Launch Funding (OLF) in addition to equity investments this year. This investment structure is designed to attract innovative space healthcare research ideas to the Humans In Space platform and drive orbital experimentation.
今年,人類在空間挑戰賽的獎金結構與去年相比發生了重大變化。雖然它在2023年爲獲勝的初創企業提供了股權投資和爲研究團隊提供了研究資金,但今年的獎金設置已擴展到包括軌道發射資金(OLF)作爲股權投資的一部分。這一投資結構旨在吸引創新的空間醫療研究理念參與人類在空間平台,並推動軌道實驗。
The OLF aims to provide selected teams, regardless of their application type, the opportunity to send their experiments to the International Space Station (ISS) for testing in an actual space environment. Among the finalists, teams capable of conducting space experiments within a short-term period (18 months) are selected as the final winners. Meanwhile, others needing additional preparation are selected as the HIS Catalyst group. Both groups will receive support to advance their space experiments. This year, the OLF category attracted over 70 teams from 11 countries, including South Korea, the United States, Canada, Germany, and the United Kingdom, highlighting a highly competitive field.
OLF旨在爲所有申請類型的選定團隊提供機會,將他們的實驗發送到國際空間站(ISS),以在實際的太空環境中進行測試。在入圍的團隊中,能夠在短期內(18個月)進行太空實驗的團隊被選爲最終贏家。同時,需要額外準備的其他團隊被選爲HIS Catalyst小組。兩個團隊都將獲得支持,以推進他們的太空實驗。今年,OLF類別吸引了來自11個國家的70多支團隊,包括韓國、美國、加拿大、德國和英國,突顯出一個競爭激烈的領域。
A total of 56 judges from esteemed organizations, including NASA, the French Institute for Space Medicine and Physiology (MEDES), the Harvard Center for Space Medicine Research, Axiom Space, and Redwire, conducted the application and final evaluation. In October, 11 startups and researchers advanced to the final round and competed in the final stage at the 75th International Astronautical Congress (IAC) held in Milan, Italy. A panel of 22 judges selected 4 teams of the final winners and 2 teams of the HIS Catalyst through the evaluation based on importance, scalability, feasibility, and the validity of the expected outcomes.
來自知名機構的共56名評委,包括NASA、法國空間醫學和生理學研究所(MEDES)、哈佛空間醫學研究中心、Axiom Space和Redwire,進行了申請和最終評估。10月,11家初創企業和研究人員晉級到決賽,並在意大利米蘭舉行的第75屆國際宇航大會(IAC)進入最後階段進行競爭。22名評委根據重要性、可擴展性、可行性和預期結果的有效性進行評估,選出了4支最終獲勝團隊和2支HIS Catalyst團隊。
In the equity investment group, Exobiosphere, a Luxembourg-based startup providing services to validate drug candidates using microgravity; Prometheus Life Technologies, a Swiss-based startup producing high-quality organoids in space; Ejenta, a U.S.-based startup offering AI-powered remote health monitoring and diagnostic solutions for astronauts, will receive USD 50,000 in funding, respectively.
在股權投資組中,總部位於盧森堡的初創公司Exobiosphere,提供利用微重力驗證藥物候選者的服務;總部位於瑞士的初創公司Prometheus Life Technologies,在太空中生產高質量的類器官;總部位於美國的初創公司Ejenta,提供人工智能驅動的宇航員遠程健康監測和診斷解決方案,將分別獲得50,000美元的資助。
In the OLF group, Dr. Charles Chiu's team from the University of California, San Francisco, developing diagnostic solutions for infectious diseases in space, was selected to receive up to USD 250,000 in funding. Through this investment, Dr. Chiu's experiment will be launched into space within the next 18 months.
在OLF小組中,加州大學舊金山分校的Dr. Charles Chiu團隊開發用於太空中感染疾病的診斷解決方案,獲得了最高可達250,000美元的資助。通過這項投資,Dr. Chiu的實驗將在未來18個月內發射到太空。
In the HIS Catalyst group, Scott Ritter from the German Aerospace Agency (DLR), who developed a portable diagnostic tool for Spaceflight-Associated Neuro-Ocular Syndrome (SANS), and Dr. JangKeun Kim from South Korea, who is studying genetic changes in microgravity, were selected. They will undergo a one-year preparation process to meet the requirements of the OLF category, and will be eligible to receive OLF support if they fulfill these conditions.
在HIS Catalyst小組中,來自德國航空航天局(DLR)的Scott Ritter開發了一種便攜式診斷工具,用於航天相關神經眼症(SANS),以及來自韓國的Dr. JangKeun Kim,他正在研究微重力下的基因變化。他們將接受爲期一年的準備過程,以滿足OLF類別的要求,如果滿足這些條件,將有資格獲得OLF壓力位。
Teams selected for equity investment and OLF will receive funding tailored to their specific conditions to accelerate their space business and research. All selected teams, including those in the HIS Catalyst group, will attend the HIS Accelerator Program, which provides mentorship and technical support to advance their research and prepare for space experiments. Moreover, they will gain opportunities to collaborate with various partners within the HIS ecosystem.
被選中進行股權投資和OLF的團隊將獲得量身定製的資金,以加速他們的太空業務和研究。所有被選中的團隊,包括HIS Catalyst小組的成員,將參加HIS加速器項目,該項目提供指導和技術支持,以推進他們的研究併爲太空實驗做準備。此外,他們將獲得與HIS生態系統內各種合作伙伴合作的機會。
Jack Lim, the Executive Director of Boryung's Strategic Investment Division, stated, "As we operate the 3rd year of the HIS Challenge program, we have observed both the program's expansion and the increasing professionalism and technical expertise of its applicants." He added, "This year's program holds significant meaning as we collaborated with a panel of judges specializing in space healthcare and engaged with high-caliber researchers and entrepreneurs dedicated to solving critical problems. With growing interest and expectations for this program within the space healthcare industry, we are committed to building a global ecosystem for space healthcare."
Boryung戰略投資部執行董事Jack Lim表示:「在我們進行HIS挑戰項目的第三年時,我們觀察到該項目的擴展以及申請者專業性和技術專長的提升。」他補充道:「今年的項目具有重要意義,因爲我們與專注於太空醫療的評審小組合作,並與致力於解決關鍵問題的高水平研究人員和企業家進行交流。隨着太空醫療行業對此項目的興趣和期望不斷增加,我們致力於建立全球太空醫療生態系統。」
Meanwhile, at the 75th IAC, Boryung featured an engaging Astronaut Talk Session with Koichi Wakata, the Japanese astronaut with the most spaceflights, who shared insights on space healthcare and received the Creative Booth Award for its innovative exhibit showcasing space medicine and healthcare advancements. Furthermore, Boryung signed MOUs with key partners, including Intuitive Machines and the German Aerospace Center (DLR), to advance space healthcare research and solidify its role in fostering a global space healthcare ecosystem.
與此同時,在第75屆國際宇航大會上,Boryung舉辦了一場引人入勝的宇航員講座,邀請日本宇航員Wakata Koichi,他是進行太空飛行最多的宇航員,分享了關於太空醫療的見解,並因其展示太空醫學和醫療進展的創新展品獲得了創意展位獎。此外,Boryung與包括Intuitive Machines和德國航空航天中心(DLR)在內的關鍵合作伙伴簽署了諒解備忘錄,以推進太空醫療研究並鞏固其在促進全球太空醫療生態系統中的角色。
SOURCE Boryung
來源:保齡(Boryung)